We start this week's episode by interviewing Dr. Alasdair Munro, a pediatrics infectious disease expert, on the risk of spread of COVID-19 in children and through schools. We end with an interview with Dr. Stefan Baral, a field epidemiologist studying COVID-19, on the nature of public health during a global pandemic.

This week we have a two-hour-long, far-ranging interview with Dr. John Ioannidis of Stanford University on, broadly, meta-research and COVID-19 - including his recent controversies. We end the episode with an interview with Dr. Mary-Elizabeth Percival of the University of Washington on her new paper out now in Haematologica: "Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility".

This week's episode is all about COVID-19. We discuss general COVID-19 health policy and how spread of SARS-CoV-2 has been managed and should be managed; we discuss whether or not schools should be re-opened; and we discuss Dr. Scott Atlas's views. Our special guests are political scientist Dr. Vladimir Kogan, epidemiologist Dr. Daniel Morgan, and health economist Dr. Jay Bhattacharya.

We start this week's episode by critically examining the new paper titled "Racial/Ethnic Variation in Nasal Gene Expression of Transmembrane Serine Protease 2 (TMPRSS2)" and asking, is it racist? After that, we discuss advances in prostate cancer imaging with two imaging specialists from Memorial Sloan Kettering Cancer Center, Drs. Anton Becker and Sungmin Woo. Finally, we have a far-reaching interview with Dr. Thomas Newman of University of California San Francisco on clinical epidemiology and his new book Evidence-Based Diagnosis: An Introduction to Clinical Epidemiology.

This week's monologue touches on the credibility of expert speakers, evaluating the COVID-19 lockdown as health policy, and the anti-affirmative action white paper written by Dr. Norman Wang and its controversy. In the second half of the episode we interview Professor Darrel Francis of Imperial College London on COVID-19 cardiology and Vascepa.

We have a number of topics for you this week! Among them, we cover the issue of colon cancer screening, especially in the light of Chadwick Boseman's recent passing. We interview Jonathan Darrow, an Assistant Professor at Harvard Medical School and faculty at Brigham and Women's Hospital, on patent litigation and the recent patent appeal for Vascepa. Finally, we interview Dr. Toby Richards, Professor of Surgery, on running clinical trials and, specifically, the results of his recent trial PREVENTT, out now in The Lancet.

This week we take a deep dive into two recently published studies, their surrounding controversy, and the broader implications. The first study was published in the journal Proceedings of the National Academy of Sciences of the USA and is titled "Physician–patient racial concordance and disparities in birthing mortality for newborns". The second was published in the New England Journal of Medicine and is titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer", commonly known as the HERO trial. We discuss the HERO trial with Dr. Michael Burns of Northwestern as part of our new segment, Journal Club with a Fellow.

This week we take a deep dive into two recently published studies, their surrounding controversy, and the broader implications. The first study was published in the journal Proceedings of the National Academy of Sciences of the USA and is titled "Physician–patient racial concordance and disparities in birthing mortality for newborns". The second was published in the New England Journal of Medicine and is titled "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer", commonly known as the HERO trial. We discuss the HERO trial with Dr. Michael Burns of Northwestern as part of our new segment, Journal Club with a Fellow.

We have a lot in store for you this week! We start off by evaluating two recently published studies: "Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer" (published in the Journal of Clinical Oncology: Oncology Practice) and "The Effect of Advances in Lung-Cancer Treatment on Population Mortality" (published in the New England Journal of Medicine). We talk a bit about tracking down the validity of a reference. We sit down with Dr. Branden Tarlow to discuss his thoughts on PPIs and COVID-19 acquisition. Finally, we conclude the episode by interviewing Dr. Elizabeth Eisenhauer of Queen's University in Kingston, Ontario, Canada on her career in cancer medicine.

We start this week's episode by discussing access to investigational COVID-19 vaccines and recapping the problems with the ADAURA study. We transition from there to a Question of the Week with medical student Audrey Tran of Oregon Health & Science University. Finally, we introduce a new segment - Journal Club with a Fellow. In this inaugural segment we invite Dr. Karine Tawagi of the Oschner Clinic in Louisiana to the podcast to talk about IMbrave150.

This is the recording of a LIVE episode of Plenary Session in which Dr. Sue S Yom interviewed our host, Dr. Vinay Prasad, on how he built his career and how he conceptualizes his work. There's also a surprise guest near the end! Thank you to Dr. Kaleigh Doke, Dr. Brian Kavanagh, and the Virtual Visiting Professor Network for hosting this special episode.

This week we respond to several questions sent in by listeners and then we interview Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada on MedTwitter, other recent events, and his recently published paper titled "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials".

This week we discuss two major papers: The first was just recently released in Nature and it's titled "The National Lung Matrix Trial of personalized therapy in lung cancer". The second is a few years old, but exemplifies the importance of trial design. We discuss the second paper, titled "A Randomized Trial of Intensive versus Standard Blood-Pressure Control" and published in the New England Journal of Medicine with Dr. Mark Friedberg, a health policies and performance measurement researcher.

This week's BONUS episode is a discussion of the National Clinician Scholars Program with Dr. Hilary Seligman, the head of the program at University of California, San Francisco. The deadline for the application for the 2021-2023 cohort is July 15, 2020 (very soon!), though there may be some leniency due to the pandemic.

This week we discuss recent research (and the accompanying Twitter thread) on the risk of COVID-19 among users of proton pump inhibitors (PPIs). We also hold a philosophical discussion on the research surrounding time to treatment initiation (TTI) in cancer medicine. We end the episode with an interview with Dr. Lynora Saxinger of the University of Alberta, Edmonton, a specialist in Infectious Diseases.

This BONUS episode is the recording of a lecture given on June 18, 2020 as part of Stanford's METRICS International Forum. METRICS stands for Meta-Research Innovation Center at Stanford University. This lecture is geared towards a broad audience and aims to provide a general sense of current cancer research. The lecture is titled "Cancer Meta-Research 101".

This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology. Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program".

This week we briefly cover updates on the RECOVERY trial before segueing into an interview with Dr. Andrae Vandross on Twitter (specifically #medtwitter), academic discussions, and changing your career to find your calling.

This week's episode is jam-packed with topics! We talk about the RECOVERY trial, the U.S. clinical trial infrastructure, event-free survival (EFS) and cost of care in acute myeloid leukemia, how long it takes to write papers in academic medicine, threats to public health officials, and the application to medicine of Dr. Raj Chetty's work in economics. Finally, we interview this week's special guest, Dr. Ian Tannock, on docetaxel, prostrate cancer, clinical trial appraisal, and his career in medicine.

This week we tackle the topic of tucatinib in HER2-positive breast cancer with brain metastases. We also interview Dr. Cailin O'Connor of the University of California Irvine on her research on misinformation and disinformation. We discuss her recent article in the Boston Review, titled "Hydroxychloroquine and the Political Polarization of Science", as well as her extensive body of work.